{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:53:41Z","timestamp":1757624021384,"version":"3.44.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-15780-5","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T05:29:33Z","timestamp":1755754173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mirabegron nighttime versus daytime dosing for women with overactive bladder syndrome: a randomized controlled trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Sheng-Mou","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"15780_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams, P. et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 61, 37\u201349 (2003).","journal-title":"Urology"},{"key":"15780_CR2","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.juro.2006.03.062","volume":"176","author":"MJ Hung","year":"2006","unstructured":"Hung, M. J. et al. Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis. J. Urol. 176, 636\u2013640 (2006).","journal-title":"J. Urol."},{"key":"15780_CR3","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1532-5415.1992.tb03645.x","volume":"40","author":"RB Stewart","year":"1992","unstructured":"Stewart, R. B., Moore, M. T., May, F. E., Marks, R. G. & Hale, W. E. Nocturia: A risk factor for falls in the elderly. J. Am. Geriatr. Soc. 40, 1217\u20131220 (1992).","journal-title":"J. Am. Geriatr. Soc."},{"key":"15780_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00192-008-0687-7","volume":"19","author":"MP Fitzgerald","year":"2008","unstructured":"Fitzgerald, M. P., Lemack, G., Wheeler, T. & Litman, H. J. Urinary Incontinence Treatment Network. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy. Int. Urogynecol. J. 19, 1545\u20131550 (2008).","journal-title":"Int. Urogynecol. J."},{"key":"15780_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","volume":"77","author":"CR Chapple","year":"2020","unstructured":"Chapple, C. R. et al. Safety and efficacy of mirabegron: Analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo. Eur. Urol. 77, 119\u2013128 (2020).","journal-title":"Eur. Urol."},{"key":"15780_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1185\/03007995.2016.1149806","volume":"2","author":"A Wagg","year":"2016","unstructured":"Wagg, A. et al. Oral pharmacotherapy for overactive bladder in older patients: Mirabegron as a potential alternative to antimuscarinics. Curr. Med. Res. Opin. 2, 621\u2013638 (2016).","journal-title":"Curr. Med. Res. Opin."},{"key":"15780_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/1756287212457114","volume":"4","author":"E Sacco","year":"2012","unstructured":"Sacco, E. & Bientinesi, R. Mirabegron: A review of recent data and its prospects in the management of overactive bladder. Ther. Adv. Urol. 4, 315\u2013324 (2012).","journal-title":"Ther. Adv. Urol."},{"key":"15780_CR8","first-page":"10106","volume":"27","author":"RA Petrossian","year":"2020","unstructured":"Petrossian, R. A., Dynda, D., Delfino, K., El-Zawahry, A. & McVary, K. T. Mirabegron improves sleep measures, nocturia, and lower urinary tract symptoms in those with urinary symptoms associated with disordered sleep. Can. J. Urol. 27, 10106\u201310117 (2020).","journal-title":"Can. J. Urol."},{"issue":"17","key":"15780_CR9","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s40265-017-0832-z","volume":"77","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. A review of food-drug interactions on oral drug absorption. Drugs 77(17), 1833\u20131855 (2017).","journal-title":"Drugs"},{"issue":"2","key":"15780_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/jsxmed\/qdad163","volume":"21","author":"RA Kloner","year":"2024","unstructured":"Kloner, R. A. et al. Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. J. Sex. Med. 21(2), 90\u2013116 (2024).","journal-title":"J. Sex. Med."},{"issue":"3","key":"15780_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1023\/A:1017504830834","volume":"32","author":"O G\u00fcl","year":"2001","unstructured":"G\u00fcl, O., Ero\u011flu, M. & Ozok, U. Use of terazosine in patients with chronic pelvic pain syndrome and evaluation by prostatitis symptom score index. Int. Urol. Nephrol. 32(3), 433\u2013436 (2001).","journal-title":"Int. Urol. Nephrol."},{"issue":"6","key":"15780_CR12","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.21037\/apm-21-1405","volume":"10","author":"H Jiang","year":"2021","unstructured":"Jiang, H., Yu, Z., Liu, J. & Zhang, W. Bedtime administration of antihypertensive medication can reduce morning blood pressure surges in hypertensive patients: A systematic review and meta-analysis. Ann. Palliat. Med. 10(6), 6841\u20136849 (2021).","journal-title":"Ann. Palliat. Med."},{"issue":"4","key":"15780_CR13","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/MOL.0000000000000524","volume":"29","author":"K Awad","year":"2018","unstructured":"Awad, K. & Banach, M. The optimal time of day for statin administration: a review of current evidence. Curr. Opin. Lipidol. 29(4), 340\u2013345 (2018).","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"15780_CR14","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1164\/ajrccm\/146.6.1524","volume":"146","author":"WR Beam","year":"1992","unstructured":"Beam, W. R., Weiner, D. E. & Martin, R. J. Timing of prednisone and alterations of airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 146(6), 1524\u20131530 (1992).","journal-title":"Am. Rev. Respir. Dis."},{"issue":"6 Pt 1","key":"15780_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0091-6749(97)70272-0","volume":"100","author":"DJ Pincus","year":"1997","unstructured":"Pincus, D. J., Humeston, T. R. & Martin, R. J. Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy. J. Allergy. Clin. Immunol. 100(6 Pt 1), 771\u2013774 (1997).","journal-title":"J. Allergy. Clin. Immunol."},{"key":"15780_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/jog.13438","volume":"43","author":"KH Tsai","year":"2017","unstructured":"Tsai, K. H., Hsiao, S. M. & Lin, H. H. Tolterodine treatment of women with overactive bladder syndrome: Comparison of night-time and daytime dosing for nocturia. J. Obstet. Gynaecol. Res. 43, 1719\u20131725 (2017).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"15780_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1097\/01.ju.0000165461.38088.7b","volume":"174","author":"A Nixon","year":"2005","unstructured":"Nixon, A. et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J. Urol. 174, 604\u2013607 (2005).","journal-title":"J. Urol."},{"issue":"2","key":"15780_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","volume":"68","author":"Y Homma","year":"2006","unstructured":"Homma, Y. et al. Symptom assessment tool for overactive bladder syndrome\u2013overactive bladder symptom score. Urology 68(2), 318\u2013323 (2006).","journal-title":"Urology"},{"issue":"12","key":"15780_CR19","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","volume":"104","author":"CJ Kelleher","year":"1997","unstructured":"Kelleher, C. J., Cardozo, L. D., Khullar, V. & Salvatore, S. A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. 104(12), 1374\u20131379 (1997).","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"3","key":"15780_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/nau.22394","volume":"33","author":"SM Hsiao","year":"2014","unstructured":"Hsiao, S. M., Lin, H. H. & Kuo, H. C. Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome. Neurourol. Urodyn. 33(3), 331\u2013334 (2014).","journal-title":"Neurourol. Urodyn."},{"key":"15780_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/nau.10066","volume":"21","author":"W Sch\u00e4fer","year":"2002","unstructured":"Sch\u00e4fer, W. et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol. Urodyn. 21, 261\u2013274 (2002).","journal-title":"Neurourol. Urodyn."},{"key":"15780_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen, B. T. et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int. Urogynecol. J. 21, 5\u201326 (2010).","journal-title":"Int. Urogynecol. J."},{"issue":"6","key":"15780_CR23","doi-asserted-by":"publisher","first-page":"890","DOI":"10.4103\/idoj.IDOJ_130_20","volume":"11","author":"K Kishore","year":"2020","unstructured":"Kishore, K. & Mahajan, R. Understanding superiority, noninferiority, and equivalence for clinical trials. Indian. Dermatol. Online. J. 11(6), 890\u2013894 (2020).","journal-title":"Indian. Dermatol. Online. J."},{"key":"15780_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s13063-018-2885-z","volume":"19","author":"DT Dunn","year":"2018","unstructured":"Dunn, D. T., Copas, A. J. & Brocklehurst, P. Superiority and non-inferiority: Two sides of the same coin?. Trials 19, 499 (2018).","journal-title":"Trials"},{"key":"15780_CR25","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40261-012-0031-3","volume":"33","author":"J Dickinson","year":"2013","unstructured":"Dickinson, J. et al. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin. Drug Investig. 33, 11\u201323 (2013).","journal-title":"Clin. Drug Investig."},{"key":"15780_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.pbb.2008.02.020","volume":"89","author":"DH Overstreet","year":"2008","unstructured":"Overstreet, D. H., Stemmelin, J. & Griebel, G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacol. Biochem. Behav. 89, 623\u2013626 (2008).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"15780_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/sj.npp.1301424","volume":"33","author":"J Stemmelin","year":"2008","unstructured":"Stemmelin, J. et al. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33, 574\u2013587 (2008).","journal-title":"Neuropsychopharmacology"},{"key":"15780_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.euroneuro.2010.04.006","volume":"20","author":"A Tamburella","year":"2010","unstructured":"Tamburella, A., Micale, V., Leggio, G. M. & Drago, F. The beta3 adrenoceptor agonist, amibegron (SR58611A) counteracts stress-induced behavioral and neurochemical changes. Eur. Neuropsychopharmacol. 20, 704\u2013713 (2010).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"15780_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejphar.2007.06.048","volume":"573","author":"D Consoli","year":"2007","unstructured":"Consoli, D., Leggio, G. M., Mazzola, C., Micale, V. & Drago, F. Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant\/anxiolytic drugs?. Eur. J. Pharmacol. 573, 139\u2013147 (2007).","journal-title":"Eur. J. Pharmacol."},{"issue":"suppl 4","key":"15780_CR30","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765202120210638","volume":"93","author":"MH Tanyeri","year":"2021","unstructured":"Tanyeri, M. H. et al. Effects of mirabegron on depression, anxiety, learning and memory in mice. An. Acad. Bras. Cienc. 93(suppl 4), e20210638 (2021).","journal-title":"An. Acad. Bras. Cienc."},{"issue":"3","key":"15780_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000497282","volume":"102","author":"M Kinjo","year":"2019","unstructured":"Kinjo, M., Yamaguchi, T., Tambo, M., Okegawa, T. & Fukuhara, H. Effects of mirabegron on anxiety and depression in female patients with overactive bladder. Urol. Int. 102(3), 331\u2013335 (2019).","journal-title":"Urol. Int."},{"issue":"Suppl 1","key":"15780_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.5213\/inj.2448002.001","volume":"28","author":"J Kwon","year":"2024","unstructured":"Kwon, J. et al. Pathophysiology of overactive bladder and pharmacologic treatments including \u03b23-adrenoceptor agonists -basic research perspectives. Int. Neurourol. J. 28(Suppl 1), 12\u201333 (2024).","journal-title":"Int. Neurourol. J."},{"issue":"10","key":"15780_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","volume":"34","author":"W Krauwinkel","year":"2012","unstructured":"Krauwinkel, W. et al. Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: Results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin. Ther. 34(10), 2144\u20132160 (2012).","journal-title":"Clin. Ther."},{"issue":"9","key":"15780_CR34","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/iju.14608","volume":"28","author":"T Suzuki","year":"2021","unstructured":"Suzuki, T. et al. Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: A multicenter randomized trial. Int. J. Urol. 28(9), 944\u2013949 (2021).","journal-title":"Int. J. Urol."},{"issue":"1","key":"15780_CR35","first-page":"30","volume":"32","author":"CL Lee","year":"2019","unstructured":"Lee, C. L., Ong, H. L. & Kuo, H. C. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive bladder. Tzu. Chi. Med. J. 32(1), 30\u201335 (2019).","journal-title":"Tzu. Chi. Med. J."},{"key":"15780_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B Olsson","year":"2001","unstructured":"Olsson, B. & Szamozi, J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin. Pharmacokinet. 40, 227\u2013235 (2001).","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"15780_CR37","doi-asserted-by":"publisher","first-page":"7499","DOI":"10.1038\/s41598-024-58036-4","volume":"14","author":"SM Hsiao","year":"2024","unstructured":"Hsiao, S. M. Predictors of non-persistence in women with overactive bladder syndrome. Sci. Rep. 14(1), 7499 (2024).","journal-title":"Sci. Rep."},{"issue":"1","key":"15780_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron, A. P. et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J. Urol. 212(1), 11\u201320 (2024).","journal-title":"J. Urol."},{"issue":"1","key":"15780_CR39","doi-asserted-by":"publisher","first-page":"18472","DOI":"10.1038\/s41598-020-75567-8","volume":"10","author":"WY Wu","year":"2020","unstructured":"Wu, W. Y., Hsiao, S. M., Wu, P. C. & Lin, H. H. Test-retest reliability of the 20-min pad test with infusion of strong-desired volume in the bladder for female urodynamic stress incontinence. Sci. Rep. 10(1), 18472 (2020).","journal-title":"Sci. Rep."},{"key":"15780_CR40","volume-title":"Urodynamic Testing and Interpretation in StatPearls","author":"M Yao","year":"2025","unstructured":"Yao, M. & Simoes, A. Urodynamic Testing and Interpretation in StatPearls (StatPearls, Treasure Island, 2025)."},{"issue":"5","key":"15780_CR41","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1002\/nau.23124","volume":"36","author":"PFWM Rosier","year":"2017","unstructured":"Rosier, P. F. W. M. et al. International Continence Society good urodynamic practices and terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol. Urodyn. 36(5), 1243\u20131260 (2017).","journal-title":"Neurourol. Urodyn."},{"issue":"2","key":"15780_CR42","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/nau.23897","volume":"38","author":"C D\u2019Ancona","year":"2019","unstructured":"D\u2019Ancona, C. et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol. Urodyn. 38(2), 433\u2013477 (2019).","journal-title":"Neurourol. Urodyn."},{"issue":"1","key":"15780_CR43","volume":"4","author":"AK Kim","year":"2017","unstructured":"Kim, A. K. & Hill, W. G. Effect of filling rate on cystometric parameters in young and middle aged mice. Bladder (San Franc). 4(1), e28 (2017).","journal-title":"Bladder (San Franc)."},{"key":"15780_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/003655902320765890","volume":"210","author":"B Klevmark","year":"2002","unstructured":"Klevmark, B. Volume threshold for micturition. Influence of filling rate on sensory and motor bladder function. Scand. J. Urol. Nephrol. Suppl. 210, 6\u201310 (2002).","journal-title":"Scand. J. Urol. Nephrol. Suppl."},{"issue":"2","key":"15780_CR45","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/JU.0000000000000199","volume":"202","author":"EJ Redmond","year":"2019","unstructured":"Redmond, E. J., O\u2019Kelly, T. & Flood, H. D. The effect of bladder filling rate on the voiding behavior of patients with overactive bladder. J. Urol. 202(2), 326\u2013332 (2019).","journal-title":"J. Urol."},{"issue":"6","key":"15780_CR46","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jfma.2023.12.007","volume":"123","author":"SM Hsiao","year":"2024","unstructured":"Hsiao, S. M. & Chang, S. R. Effect of tibolone versus hormone replacement therapy on lower urinary tract symptoms and sexual function. J. Formos. Med. Assoc. 123(6), 710\u2013715 (2024).","journal-title":"J. Formos. Med. Assoc."},{"issue":"6","key":"15780_CR47","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","volume":"32","author":"CR Chapple","year":"2014","unstructured":"Chapple, C. R. et al. Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World J. Urol. 32(6), 1565\u20131572 (2014).","journal-title":"World J. Urol."},{"issue":"3","key":"15780_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jfma.2018.08.014","volume":"118","author":"CH Liao","year":"2019","unstructured":"Liao, C. H. & Kuo, H. C. Mirabegron escalation to 50 mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder. J. Formos. Med. Assoc. 118(3), 700\u2013706 (2019).","journal-title":"J. Formos. Med. Assoc."},{"issue":"1","key":"15780_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40261-013-0146-1","volume":"34","author":"H Iitsuka","year":"2014","unstructured":"Iitsuka, H. et al. Pharmacokinetics of mirabegron, a \u03b23-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: Results from single- and multiple-dose studies. Clin. Drug. Investig. 34(1), 27\u201335 (2014).","journal-title":"Clin. Drug. Investig."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15780-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15780-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T10:02:26Z","timestamp":1757412146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-15780-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15780"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-15780-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"19 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Research Ethics Committee (Far Eastern Memorial Hospital Research Ethics Review Committee, No. 106001-F, approval date: 01 August 2017) at Far Eastern Memorial Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"30687"}}